| dc.creator |
Calmy, A |
|
| dc.creator |
Pascual, F |
|
| dc.creator |
Ford, N |
|
| dc.date |
2004 |
|
| dc.date.accessioned |
2017-01-31T07:11:08Z |
|
| dc.date.available |
2017-01-31T07:11:08Z |
|
| dc.identifier |
First-line and second-line antiretroviral therapy., 364 (9431):329; author reply 330 Lancet |
|
| dc.identifier |
1474-547X |
|
| dc.identifier |
15276388 |
|
| dc.identifier |
10.1016/S0140-6736(04)16716-0 |
|
| dc.identifier |
http://hdl.handle.net/10144/28172 |
|
| dc.identifier |
http://fieldresearch.msf.org/msf/handle/10144/28172 |
|
| dc.identifier |
Lancet |
|
| dc.identifier.uri |
http://dspace.mediu.edu.my:8181/xmlui/handle/10144/28172 |
|
| dc.language |
en |
|
| dc.publisher |
Elsevier |
|
| dc.rights |
Reproduced on this site with permission of Elsevier Ltd. Please see [url]http://www.thelancet.com/[/url] for further relevant comment. |
|
| dc.title |
First-line and second-line antiretroviral therapy. |
|